THURSDAY, April 17, 2025 (HealthDay News) — Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for Alzheimer disease and related dementias (ADRDs) among people with type 2 diabetes (T2D), according to a study published online April 7 in JAMA Neurology. Huilin Tang, Ph.D., from the […]
The post GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM first appeared on Physician’s Weekly.
